Back to Search

Selnoflast for Atherosclerosis and Heart Risk

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

Recruiting Phase 2 Interventional Study
Atherosclerosis
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 80
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
162 (estimated)
Sponsor
Genentech, Inc. · Industry
Who this trial is looking for

This trial is looking for participants with atherosclerosis who are at high risk for serious heart problems. By joining, I will receive either the study drug selnoflast or a placebo while continuing my standard treatment.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with atherosclerosis
  • I have specific test results showing high levels of vascular inflammation
  • I am currently on standard treatment for atherosclerosis

You may not be able to join if

  • I have Class III or IV heart failure
  • I have uncontrolled heart rhythm problems
  • I have uncontrolled high blood pressure
  • I am known to be immunocompromised
  • I have planned surgery during the study
  • I have had cancer in the last 5 years, except for certain treated types
  • I tested positive for hepatitis B, hepatitis C, or HIV
  • I received certain vaccines shortly before starting the study

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The main purpose of the study is to evaluate the efficacy of selnoflast compared with placebo in participants with atherosclerosis, at high-risk for major adverse cardiovascular event (MACE), who are currently on standard-of-care (SOC) therapy.

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Confirmed evidence of atherosclerosis * Left or right carotid TBR ≥ 1.8 or aorta TBR ≥ 2.0 on centrally-assessed 18F-fluorodeoxyglucose-Positron Emission Tomography (18F-FDG-PET) scan * Stable treatment of atherosclerosis through the use of SOC medications or revascularization…
Contacts

Reference Study ID Number: GC46102 https://forpatients.roche.com/

888-662-6728

global-roche-genentech-trials@gene.com

CONTACT

Fastest response: use the inquiry form. No email attachments https://www.gene.com/contact-us/submit-medical-inquiry

CONTACT

NCT ID: NCT07448038 Source: ClinicalTrials.gov